Sanjeeve Bala, MD, MPH, joined Neogene as Head, Regulatory Affairs, in September 2022. His industry career began at BeiGene USA, where he served as head of North America/Latin America Regulatory Affairs, developing strategy and overseeing multiple successful submissions to US FDA, HealthCanada, and other global health authorities. Prior to this, Sanjeeve was a Medical Officer and then a Clinical Team Leader at the US FDA Division of Oncology Products 1 in the Center for Drug Evaluation and Research, during which time he participated in or oversaw the review of multiple oncology drug and device products, including through collaborations with CDRH and CBER. Before joining FDA, Sanjeeve was on staff at the US National Cancer Institute, part of the National Institutes of Health, where he conducted early-phase clinical oncology research and where he also completed his fellowships in medical oncology, hematology, and cancer prevention. Sanjeeve got his start in oncology as a Clinical Fellow in the Surgery Branch, NCI, under the leadership of Dr. Steven Rosenberg, where he contributed to clinical immunotherapy research programs and surgical oncology research studies and published basic research on a murine model of adoptive cell therapy for cancer.